Document:

Service Agreement with Dr. Bernd Seizinger dated June 1, 2003

  
 Exhibit 10.14

  
 SERVICE AGREEMENT 
  
 between 
  
 GPC Biotech AG 
 Fraunhoferstrasse. 20 
 82152 Martinsried 
  
 (hereinafter “Company”) 
  
 and 
  
 Dr. Bernd Robert Seizinger 
 Gabriel-Max-Strasse 26 
 81545 Munich 
  
 (hereinafter “Chief Executive Officer”) 
  
 § 1 
  
 Responsibilities 
  

	1.	Through the resolution adopted by the Supervisory Board on May 20, 2003, the Chief Executive Officer was appointed as member of the Management Board and as its chairman (CEO) for an
additional period of five years, effective June 1, 2003. 

  

	2.	In conjunction with the other appointed members of the Management Board, the Chief Executive Officer shall conduct the affairs of the Company with the due care and diligence of a
prudent and conscientious business manager pursuant to the provisions of law, the Articles of Incorporation, the Rules of Internal Procedure for the Management Board as issued by the Supervisory Board, a plan for the allocation of duties, and this
Agreement. In particular, the Chief Executive Officer shall comply with the instructions of the Supervisory Board. 

  

	3.	The Chief Executive Officer shall always act exclusively for the good of the Company and of any enterprises affiliated with it in the future and shall, to be best of his ability,
support and promote its interests and objectives, in particular the enhancement of the Company’s shareholder value. 

  

	4.	Other responsibilities as described specifically in the appendix are incumbent upon the Chief Executive Officer. 

  

	5.	The Chief Executive Officer is obligated to assume, upon demand by the Supervisory Board, Supervisory Board mandates or a seat in similar supervisory bodies in other companies that
are affiliated with the Company as well as managerial functions at subsidiaries or enterprises affiliated with the Company. He shall resign from such positions at any time upon demand by the Supervisory Board, and no later than upon the termination
of his appointment as Chief Executive Officer. 

  
 § 2 
  
 Term of Contract 
  

	1.	This Agreement commences on June 1, 2003, with premature dissolution of the Management Agreement of May 4, 2000. It is entered into for a fixed term of 5 years running to June 1,
2008. The right to termination for cause (§ 12) remains unaffected thereby. 

  

	2.	By no later than twelve months prior to the expiration of this Agreement, the chairman of the Supervisory Board shall inform the Chief Executive Officer whether the Supervisory
Board intends to reappoint the Chief Executive Officer as chief executive officer and whether it is prepared to extend this Service Agreement with him in keeping with the term of the reappointment or to enter into a new contract of employment
subject to different terms and conditions. The Chief Executive Officer and the chairman of the Supervisory Board shall thereupon reach an Agreement on a contract of employment acceptable to both sides within 3 months. 

  

	3.	If the Supervisory Board resolves not to appoint the Chief Executive Officer to a new term in office and has accordingly not made the Chief Executive Officer an offer for the
extension of contract under comparable terms and conditions by June 1, 2007, then the Chief Executive Officer is entitled to demand his release, effective December 1, 2007, from all employment obligations with continued payment of his emoluments.
Irrespective thereof, this Agreement shall remain in force until June 1, 2008. 

  
 Moreover, the Chief Executive Officer shall be paid a one-time settlement in the amount of 200% (two hundred percent) of the total of the last annual salary and of the average of the two annual bonuses last received.
This amount shall be paid out on June 1, 2008. 
  

 Moreover, all options, convertible bonds, phantom stock, and all rights that carry an entitlement to
acquire stock in the Company that have been issued to the Chief Executive Officer up to that time shall vest (“accelerated vesting”). The Chief Executive Officer shall moreover be granted an extension of the period within which stock
options, convertible bonds, phantom stock, and all other rights that carry an entitlement to acquire stock in the Company must be exercised, with said extension running to 3 years following the end of the term of contract (extended to June 1, 2011).

  
 § 3 
  
 Remuneration 
  

	1.	The Chief Executive Officer shall receive for his activity a gross annual salary (base salary) in the amount of 

  
 € 295,136 (two hundred ninety-five thousand one hundred thirty-six EUROS)

  
 plus 
  
 $131,875 (one hundred thirty-one thousand eight hundred seventy-five US
Dollars), 
  
 payable in 12 equal monthly installments.

  
 The annual salary shall be reviewed by the Supervisory Board
with regard to a possible increase. No increase is planned for 2003. The next annual review for a possible increase in the gross salary is planned for Q2, 2004. An adjustment of the German share (in EUR) relative to the U.S. share (in U.S. $) of the
Chief Executive Officer’s gross salary is possible at any time with the approval of the Supervisory Board, so as to reflect a possible change in the relative amount of time spent by the Chief Executive Officer working for the Company in Germany
relative to the USA. 
  

	2.	Moreover, the Chief Executive Officer shall continue to receive support for maintaining double households (“double-household allowance”) with respect to the second
residence in the USA in the amount of US $3,000 (three thousand US Dollars) per month, which shall be paid out in the USA. This amount too shall be reviewed by the Supervisory Board on an annual basis with regard to a possible increase.

  

	3.	In addition to the remuneration specified in Paragraphs 1 and 2, the Chief Executive Officer shall receive special remuneration to be decided by the Supervisory Board within the
meaning of § 86 AktG (Stock Corporation Act) as additional performance-based compensation (“performance cash bonus”). This “performance cash bonus” shall - in the event of performance by the Chief Executive Officer - be in
keeping with the standards of his position and field. However, whether this remuneration will be granted and the amount thereof are at the absolute discretion of the Supervisory Board. 

  

	3.	 In addition to the remuneration defined in Paragraphs 1 through 3, and in addition to the “performance” stock options and/or convertible bonds to be
decided by the Supervisory Board on an annual basis, the Chief Executive Officer shall, at the earliest possible time following the 

  

	 	 
signing of this Agreement, receive as part of his remuneration a one-time amount of 300,000 (three hundred thousand) stock options with a strike price
corresponding to the closing price of the GPC Biotech stock on the date of issue of the stock options to the Chief Executive Officer. This presupposes that the new “contingent capital” necessary therefor has been created by the GPC Biotech
2004 General Meeting of Shareholders. The conversion privilege certificated by the stock options shall be exercised in accordance with the applicable option terms. In this regard, the options are subject to a special call right (“vesting”)
staggered in annual tranches not to exceed 4 years (i.e., “vesting” of 75,000 options per year). However, the fourth and last tranche of 75,000 stock options shall not vest later than May 30, 2008, and thus one day prior to the end of
contract. 

  

	5.	In the event of a change of control, the Addendum to Service Agreement approved by the Supervisory Board and signed on May 1, 2003 by the Supervisory Board chairman and the Chief
Executive Officer enters into force. The definition of “Change of Control” and the associated payments (premature “vesting” of stock options, convertible bonds, phantom stock, other rights that carry an entitlement to acquire
stock in the Company, etc., as well as cash payments) are set forth in detail therein. The Addendum to Service Agreement is attached hereto. 

  
 With regard to other residual claims under this Service Agreement of June 1, 2003 (upon premature dissolution of this Service Agreement as a result of
Change of Control), and the claims under the Addendum to Service Agreement of May 1, 2003, upon a Change of Control, the better set of terms and conditions enters into force (the better set of terms and conditions with regard to cash payments,
premature “vesting” of stock options, convertible bonds, etc., and extended period for exercising the options, convertible bonds, etc.), but not both (i.e., the claims under the two Agreements are not combined). 
  

	6.	The entirety of the Chief Executive Officer’s claim arising from his activity shall be deemed settled by the remuneration pursuant to the preceding paragraphs.

  
 § 4 
  
 Other Benefits 
  

	1.	The Company is obligated to reimburse the Chief Executive Officer - where applicable, in accordance with the Internal Guidelines of the Company - for necessary and reasonable
expenses, including travel and entertainment costs. The expenses shall in each case be documented in accordance with tax law, unless flat-rate amounts permitted under tax law are settled. 

  
 § 5 
  
 Vacation 
  

	1.	The Chief Executive Officer is entitled to an annual vacation of 30 working days. 

  

	2.	The schedule shall be decided in coordination with the Company, taking into account the business interests of the Company. 

  

	3.	 If the Chief Executive Officer is unable to use some or all of his vacation time by year’s end owing to business or personal reasons, he remains entitled to
said vacation time until June 30 of 

  

	 	 
the subsequent year. If some or part of the vacation time cannot be used by that date owing to business reasons, the vacation claim lapses. There is no
entitlement to compensation for unused vacation time. 

  

	4.	If some or all of the vacation time cannot be granted owing to termination of the employment relationship, a corresponding settlement shall be paid to the Chief Executive Officer.

  
 § 6 
  
 Remuneration During Illness 
  

	1.	In the event of illness, monthly remuneration in the amount of 100% of the monthly remuneration pursuant to § 3, Paragraphs 1 and 2 shall continue to be paid for a period of 6
months. The continued payment of emoluments shall not extend beyond the termination of this Service Agreement. 

  

	2.	Any payments made by third parties, such as those resulting from liability claims or health insurance coverage, shall be credited to payments paid by the Company insofar as the
total of such payments and the payments by the Company exceeds the net emoluments that the Chief Executive Officer would receive pursuant to § 3 if he were not unable to work. 

  
 § 7 
  
 Duties and Secondary Activity 
  

	1.	The Chief Executive Officer shall devote his entire working capacity and all of his knowledge, experience, and know-how to the service of the Company. The Chief Executive Officer is
free to set his own working hours, which shall be in keeping with his responsibilities and come to at least 40 hours per week. 

  

	2.	The assumption of offices in supervisory bodies of other enterprises or of honorary positions in organizations requires prior written approval by the Company.

  
 § 8 
  
 Business and Trade Secrets 
  
 The Chief Executive Officer is obligated to maintain full confidentiality toward third
parties with regard to all business and trade secrets, and to do so beyond the end of the contractual relationship. Any provision of confidential information to unauthorized third parties requires prior written approval by the Supervisory Board.

  

 § 9 
  

Rights From Inventions and 
  
 Suggestions for Technical Improvements 
  

	1.	The Chief Executive Officer is obligated to provide prompt written notice to the Company of any invention made by him over the course of the employment relationship that has arisen
from his activity for the company or that is substantially based on the experience or work of the company (§ 4 ArbNErfG (Employee Invention Act)). 

  

	2.	The Company is entitled within a period of 4 (four) months following the notice to lay claim to the invention through a written statement provided to the Chief Executive Officer.
The invention and all rights thereto both domestically and abroad pass to the Company upon receipt of the statement. 

  

	3.	If the Company does not lay claim to the invention within 4 (four) months, the Chief Executive Officer is entitled to freely dispose of it. 

  

	4.	A Chief Executive Officer who has made a free invention (§ 4 ArbNErfG) during the employment relationship must promptly inform the Company thereof in writing. Before the Chief
Executive Officer exploits a free invention elsewhere during the term of the employment relationship, he must first offer the Company a nonexclusive right to use the invention under reasonable terms and conditions if the invention falls within the
existing or agreed working field of the Company’s operations at the time of the offer. 

  
 The Company’s privilege expires if the Company fails to accept the free invention within 3 (three) months. 
  

	5.	The Company holds exclusive rights to inventions or technical improvements which the Chief Executive Officer has made or devised during his activity for the Company or in connection
with his activity for the Company or on the basis of work for the Company. The Chief Executive Officer assigns all such rights to the Company, and the Company hereby accepts said assignment. 

  

	6.	The provisions of the Employee Invention Act, and in particular the provisions concerning remuneration pursuant to §§ 9 ff. ArbNErfG, are otherwise inapplicable.

  

 § 10 
  

Restraint of Competition 
  
 The Chief Executive Officer is prohibited for the duration of this Agreement from working, for his own account or that of another, and on an employee or independent
contractor basis, for an enterprise that is similar to the Company or that is or could become a competitor of it. Likewise, for the duration of this Agreement the Chief Executive Officer is not permitted to found or acquire such an enterprise, to
acquire a direct or indirect interest therein, or to provide support for such an enterprise. Ownership of shares in a listed company that amounts to less than 5% of all shares and does not entitle him to exercise influence over the bodies of the
respective company shall not be deemed an interest within the meaning of the preceding provision. 
  
 § 11 
  
 Contractual Penalty 
  

	1.	For each instance of contravention of the restraint of competition within the meaning of §10 or of the secrecy obligation pursuant to § 8, the Chief Executive Officer
shall pay a contractual penalty in an amount corresponding to the average monthly remuneration received over the 12 months preceding his departure pursuant to § 3, Paragraph 1 of this Agreement. 

  

	2.	In the event of an ongoing breach, the contractual penalty pursuant to § 1 is imposed anew for each month or part of a month. 

  

	3.	Other claims by the Company arising from contravention of the restraint of competition or of the secrecy obligation are unaffected by the preceding provisions.

  
 § 12 
  
 Termination 
  

	1.	The termination of this Agreement for cause remains unaffected for both parties; the following in particular are considered cause for termination by the Company:

  

	 	a)	Violation of the substantive provisions of this Agreement or of the restrictions imposed on him in the internal relationship by provisions of law, the Articles of Incorporation, the
Management Board Rules of Internal Procedure, or instructions issued by the Supervisory Board; 

  

	 	b)	Fault upon conclusion of contract, in particular deception concerning another service or employment relationship that simultaneously entails obligations, especially in the case of
conflict of interest; 

  

	 	c)	Persistent and willful breach of work duties, especially through refusal or faulty performance of the responsibilities assumed for the Company pursuant to § 1, Paragraph 4;

  

	 	d)	Breaches of the duty of loyalty toward the Company, toward any enterprises affiliated with it in the future, toward its bodies or employees, or toward business partners of the
Company or of any enterprises affiliated with it in the future, in particular through violation of the ban on secondary activity (§ 7), the secrecy requirement (§ 8), and/or the restraint of competition (§ 10);

  

	 	e)	Other breaches of duty through willful nonobservance of qualified instructions or the deliberate provision of incomplete information to a body of the Company or to a competent
committee; 

  

	 	f)	Uncontested or proven criminal acts by the Chief Executive Officer, especially crimes against property; 

  

	 	g)	Defamation of members of bodies or of executive employees, in particular through calumny or slander; 

  

	2.	Notice of termination shall be provided by registered letter. 

  

	3.	In the event of extraordinary termination pursuant to Paragraph 1, Subparagraph c, the Chief Executive Officer shall receive the monthly remuneration pursuant to § 3, Paragraph
1 and 2 until he assumes a comparable activity in keeping with his educational background, but for no longer than until the end of the five-year term of contract. 

  

	4.	In each case of termination, the Company may, at its own discretion, and independently of the effectiveness of the termination and with reservation of its other rights, release the
Chief Executive Officer from his activity for the Company or entrust him with other responsibilities that may be regarded as appropriate with respect to the professional qualifications of the Chief Executive Officer. 

  

 § 13 
  

Surrender of Documents 
  

	1.	Upon the termination of this Agreement - or, in the case of earlier release, at the time of release - the Chief Executive Officer is obligated to return to the Company, promptly and
unsolicited, all documents, drawings, and other materials connected with his activity for the Company or relating to affairs of the Company. The Chief Executive Officer is not entitled to exercise a right of retention to such articles.

  

	2.	The Chief Executive Officer’s duty to surrender also extends to other articles belonging to the Company, such as keys and supplies. 

  
 § 14 
  
 Concluding Provisions 
  

	1.	Contractual amendments or additions must be in writing and require the approval of the Supervisory Board; this also applies to the preceding subsentence. 

 

	2.	Should individual provisions of this Agreement be or void, the validity of the remaining provisions herein shall not be affected. The void provision shall be replaced by a provision
that comes as close as possible to the economic purpose aspired to. The same situation applies to any gaps in the Agreement. 

  

	3.	This Service Agreement is governed by the laws of Germany. The exclusive venue, insofar as it is permissible, is Munich (Regional Court I). 

  

					
	 Martinsried, June 1, 2003
	 	 	 	 
			
	 /s/ Prof. Dr. Jürgen Drews
	 	 	 	 /s/ Prof. Dr. Bernd R. Seizinger

	 Prof. Dr. Jürgen Drews
 Chairman of the Supervisory Board
 GPC Biotech AG
	 	 	 	 Prof. Dr. Bernd R. Seizinger

  
 Appendix 
  

 Appendix: 
  

	•	Pursuit of an overall objective with respect to the further development of the Company and implementation of the corporate policy approved by the Supervisory Board.

  

	•	Development of a strategic plan for the Company in which the scientific, organizational, financial, and economic objectives in particular are defined. 

  

	•	Support for implementation of the strategic plan approved by the Supervisory Board. 

  

	•	Development and implementation of internal research programs for the Company for the purpose of expanding its technology and research projects. 

  

	•	Best efforts with regard to entering into research and licensing agreements under generally accepted market terms, which in each instance support the Company’s leading role in
the industry. 

  

	•	Best efforts with regard to developing, entering into, and executing new collaborations with other companies in the field of life sciences, pharmaceuticals, and biotechnology. An
essential element of execution is the achievement of agreed project goals (e.g., milestones, research commitments, etc.) 

  

	•	Effective leadership and/or cooperation with the founders of the Company, its bodies, and its project heads. 

  

	•	Hiring and maintenance of qualified personnel for the Company with above-average scientific and technical abilities and leadership qualities. 

  

	•	Development and promotion of the corporate culture on all employee and executive levels of the Company for the purpose of maximizing personnel commitment. This should be reflected
in the employee evaluation system established by the Company. 

  

	•	Drafting and implementation of long-term remuneration programs for the purpose of promoting and achieving the Company’s strategic goals. 

  

	•	Use of the expertise of the members of the Company’s Supervisory Board, Management Board, and executive personnel, and of its scientific consultants. 

 

	•	Review of the composition and, if necessary, restructuring or expansion of the team of scientific consultants with respect to the ongoing development of the Company.

  

	•	Regular review, expansion, and maintenance of the Company’s industrial property rights, especially with regard to its own patents, trademarks, expertise, and other registerable
rights, and with regard to the licensing or other use of the outside industrial property rights. 

  

	•	Promotion of the reputation and of the economic development of the Company through an appropriate approach to the press and as part of other public relations work.

  

	•	Regular support for and maintenance of relations with other nonaffiliated companies, especially with suppliers, government authorities, and institutions. 

 

	•	Active and regular support for and maintenance of relations with investors, shareholders, and banks. 

  

	•	As needed, search for attractive investments through so-called blue chip funds for the Company’s future financing activities.Addendum to Service Agreement with Dr. Seizinger dated May 1, 2003

 Exhibit 10.15 
  
 + 49 89 8565 2600 tel. 
 + 49 89 8565 2610 fax 
 www.gpc-biotech.com 
  
 

 
 GPC Biotech AG 
 Postfach 1455 
 82143 Planegg 
 Germany 
 Fraunhoferstrasse 20 
 82152 Martinsried/Munich 
 Germany 
  
 ADDENDUM TO SERVICE AGREEMENT 
  
 The Service Agreement of May 4, 2000 between GPC Biotech AG, Fraunhoferstr. 20, 82152
Martinsried/Planegg (hereinafter “Company”) and Dr. Bernd Robert Seizinger, Gabriel-Max-Strasse 20, 81545 Munich (hereinafter “Chief Executive Officer”) is hereby amended with immediate effect pursuant to § 14, Para. 1.

  
 The Addendum to Service Agreement of 9/10/2002 is hereby rescinded and
replaced by the following § 15 of the Service Agreement: 
  
 § 15 
  
 Change of Control 

 

	1.	In the event of a “change of control” (as defined below), all stock options, convertible bonds, phantom stock, and all other rights that carry an entitlement to acquire
stock in the Company that have been issued to the Chief Executive Officer up to that time shall vest (“accelerated vesting”) as soon as one shareholder or group of shareholders has acquired the majority of the voting rights in the Company,
and by no later than the time at which said acquisition has been reported to the Federal Office for Financial Services Supervision (BaFin). In the event of a merger with other companies, the aforementioned rights vest when the merger is recorded in
the Commercial Register. Moreover, the Company shall not avail itself of any of the call facilities provided in the terms of the aforementioned stock options, convertible bonds, or phantom stocks for a period of at least 5 years following a
“change of control” or until maturity. 

  
 The other obligations of the Company toward the Chief Executive Officer arising from the present Agreement remain unaffected by such a takeover. The other terms of the stock options, convertible bonds, phantom stock, and all other rights
that carry an entitlement to acquire stock in the Company remain in force unchanged. 
  

					
	 	  	GPC Biotech AG	  	Management Board:
	 	  	Munich District Court HRB 119 555	  	Prof. Dr. Bernd Seizinger (CEO)
	 	  	VAT ID No.: DE 190 457 435	  	Dr. Elmar Maier
	 	  	 	  	Dr. Sebastian Meier-Ewert
	 	  	Deutsche Bank AG, Munich (Code 700 700 10), Acct. No. 199 01 18)	  	Dr. Mirko Scherer
	 	  	Dresdner Bank AG, Munich (Code 700 800 00), Acct. No. 300 906 300	  	 
	 	  	HypoVereinsbank AG, Munich (Code) 700 202 70), Acct. No. 272 66 45	  	Chairman of the Supervisory Board
	 	  	 	  	Dr. Jürgen Drews

  

	2.	Should the Company terminate the Service Agreement for any reason other than cause pursuant to § 12, Para. 1 of the Service Agreement within two years following the
“change of control,” or should the Chief Executive Officer terminate the Service Agreement within that same period for one or more of the following reasons: 

  

	 	a)	reduction in the annual salary and/or in the envisaged bonus; 

  

	 	b)	loss of the position of Chief Executive Officer or assignment of unreasonable responsibilities (“material diminution”); or 

  

	 	c)	change of the location of the Chief Executive Officer’s place of work to a new location that is more than 50 km from his two places of work at the time of the “change of
control” (currently Fraunhoferstr. 20 in 82152 Martinsried/Planegg and 101 College Road East, Princeton, NJ 08540); 

  
 then a one-time payment shall be due to the Chief Executive Officer within 30 days, beginning with the last day of the Service Agreement. This payment
shall amount to 250% (two hundred fifty percent) of the total of 
  

	 	a)	one annual salary at the time of the “change of control” or at a later time if the annual salary is increased; and 

  

	 	b)	the average of the two annual bonuses last received prior to the date of the “change of control.” If the Chief Executive Officer has not received two annual bonuses, the
last annual bonus payment is used as the basis for calculation. 

  
 This payment can be foregone if the Company and the Chief Executive Officer agree to a higher settlement. 
  

	3.	“Change of control” is defined here as: a) the takeover, exchange, or other transfer of more than 50% of the outstanding voting rights in the Company (in one or more
steps) to a single shareholder or group of shareholders, or b) the merger of the Company with other companies (e.g., as part of a “merger” or “reverse merger”), in which the Company holds less than 50% of the outstanding voting
rights in the new company. 

  
 Martinsried/Planegg, 5/1/2003

  

							
	 Chief Executive Officer
	 	 	 	 	 	 GPC Biotech AG

	 	 	 	 	 	 	 
	 	 	 	 	 	 	 
				
	/s/ Prof. Dr. Bernd Robert Seizinger        	 	 	 	 	 	/s/ Prof. Dr. Jürgen Drews                
	 Prof. Dr. Bernd Robert Seizinger
	 	 	 	 	 	 Prof. Dr. Jürgen Drews
 Chairman of the
Supervisory Board

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00067-of-00352.parquet"}]]